Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor “What This Means” Segment Highlighting Key Learnings from First-In-Human Trial and Extension into Visceral Cancer Pain
Rhea-AI Summary
Autonomix Medical (NASDAQ: AMIX) has participated in a Virtual Investor "What This Means" segment featuring Chief Medical Officer Dr. Robert Schwartz. The discussion focused on two key aspects: the successful completion of their initial first-in-human proof-of-concept trial (PoC 1), which demonstrated meaningful pain reduction, and their plans for a market expansion study (PoC 2). The PoC 2 trial, scheduled to begin in Q2 2025, will evaluate their technology's effectiveness in treating pain across additional visceral cancers and earlier-stage pancreatic cancer. The company's technology focuses on using transvascular energy to ablate problematic nerves for pain mitigation in cancer patients.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, AMIX declined 2.14%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discusses key learnings from initial trial phase (“POC 1”) where clinically meaningful pain reduction was demonstrated
Outlines Company’s plans to initiate market expansion study (“POC 2”) into additional visceral cancers and earlier stage pancreatic cancer, expected to begin Q2 2025
Access the “What This Means” video here
THE WOODLANDS, TX, May 01, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it recently participated in a Virtual Investor “What This Means” segment.
For the segment, Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discussed the Company’s successfully met initial phase of the first-in-human proof-of-concept trial (“PoC 1”) and the advancement to a follow-on phase (“PoC 2”) evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate pain in patients with pancreatic cancer pain.
The “What This Means” video can be accessed here.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com
FAQ
What were the key results from Autonomix Medical's (AMIX) first-in-human trial?
When will Autonomix Medical (AMIX) begin its PoC 2 market expansion study?
What is the main technology being developed by Autonomix Medical (AMIX)?
What conditions will be studied in Autonomix Medical's (AMIX) PoC 2 trial?
